Posted by Michael Wonder on 01 Nov 2024
FELIQS receives US FDA fast track designation for FLQ-101, a first in class small molecule to prevent retinopathy of prematurity
1 November 2024 - FELIQS announced today that the US FDA has granted its lead asset, FLQ-101, fast track designation for the prevention of retinopathy of prematurity.
The company plans to conduct a Phase1b/2 study of FLQ-101 (tROPhy-1 study) both in the US and Japan in 1Q,2025.
